{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:27:04Z","timestamp":1788881224865,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.eplepsyres.2016.02.012","type":"journal-article","created":{"date-parts":[[2016,3,2]],"date-time":"2016-03-02T17:35:04Z","timestamp":1456940104000},"page":"79-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens"],"prefix":"10.1016","volume":"122","author":[{"given":"Manuela","family":"Contin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Alberghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmina","family":"Candela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Benini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2016.02.012_bib0005","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1111\/j.1528-1167.2007.01272.x","article-title":"Generic products of antiepileptic drugs (AEDs): is it an issue?","volume":"48","author":"Bialer","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.02.012_bib0010","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1528-1167.2010.02573.x","article-title":"Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability","volume":"51","author":"Bialer","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.02.012_bib0015","series-title":"HPLC Analysis of Antiepileptic in Serum and Plasma","author":"Chromsystems","year":"2007"},{"key":"10.1016\/j.eplepsyres.2016.02.012_bib0020","series-title":"Antiepileptic Drugs: New Advice on Switching between Different Manufacturers\u2019 Products for a Particular Drug","author":"Commission on Human Medicines UK","year":"2013"},{"key":"10.1016\/j.eplepsyres.2016.02.012_bib0025","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0378-4347(01)00302-4","article-title":"Simple and rapid liquid chromatographic-turbo ion spray mass spectrometric determination of topiramate in human plasma","volume":"761","author":"Contin","year":"2001","journal-title":"J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.eplepsyres.2016.02.012_bib0030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jchromb.2008.08.007","article-title":"Simple and validated HPLC-UV analysis of levetiracetam in deproteinized plasma of patients with epilepsy","volume":"873","author":"Contin","year":"2008","journal-title":"J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.eplepsyres.2016.02.012_bib0035","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1474-4422(07)70105-9","article-title":"Antiepileptic drugs: generic versus branded treatments","volume":"6","author":"Heaney","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2016.02.012_bib0040","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1517\/17425255.2015.989211","article-title":"Is bioavailability altered in generic versus brand anticonvulsants?","volume":"11","author":"Jankovic","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.eplepsyres.2016.02.012_bib0045","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00007691-200306000-00016","article-title":"Therapeutic drug monitoring of the newer antiepileptic drugs","volume":"25","author":"Johannessen","year":"2003","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2016.02.012_bib0050","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40263-013-0112-8","article-title":"Generic products of antiepileptic drugs: a perspective on bioequivalence, bioavailability, and formulation switches using Monte Carlo simulations","volume":"28","author":"Karalis","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2016.02.012_bib0055","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2165\/10898530-000000000-00000","article-title":"Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis","volume":"70","author":"Kesselheim","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.eplepsyres.2016.02.012_bib0060","series-title":"Sample Size Tables for Clinical Studies","author":"Machin","year":"2009"},{"issue":"Suppl. 5","key":"10.1016\/j.eplepsyres.2016.02.012_bib0065","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1528-1167.2006.00871.x","article-title":"Recommendations of the Italian League against epilepsy working group on generic products of antiepileptic drugs","volume":"47","author":"Perucca","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.02.012_bib0070","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1212\/CPJ.0b013e31828d9fc9","article-title":"Generic substitution of antiepileptic drugs. What's a clinician to do?","volume":"3","author":"Privitera","year":"2013","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.eplepsyres.2016.02.012_bib0075","first-page":"81","article-title":"The controversy over generic antiepileptic drugs","volume":"15","author":"Shaw","year":"2010","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"10.1016\/j.eplepsyres.2016.02.012_bib0080","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/TCRM.S5366","article-title":"Substitution of anticonvulsant drugs","volume":"5","author":"Steinhoff","year":"2009","journal-title":"Ther. Clin. Risk Manage."},{"key":"10.1016\/j.eplepsyres.2016.02.012_bib0085","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/j.1875-9114.2012.01099.x","article-title":"Efficacy and safety of innovator versus generic drugs in patients with epilepsy: a systematic review","volume":"32","author":"Talati","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.eplepsyres.2016.02.012_bib0090","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1345\/aph.1Q349","article-title":"Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies","volume":"45","author":"Yamada","year":"2011","journal-title":"Ann. Pharmacother."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121116300304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121116300304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:35:16Z","timestamp":1760276116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121116300304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":18,"alternative-id":["S0920121116300304"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2016.02.012","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2016.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}